Experimental protocol
| Treatment . | Monkey ID . | Age, y . | Sex . | Weight, kg . | Initial proviral load, copies/105 PBMCs . |
|---|---|---|---|---|---|
| None | C1 | 16 | Female | 19 | 519 |
| C2 | 20 | Male | 27 | 153 | |
| C3 | 11 | Male | 32 | 92 | |
| C4 | 15 | Female | 15 | 147 | |
| AZT | A1 | 14 | Female | 14 | 108 |
| A2 | 10 | Female | 22 | 86 | |
| VPA | V1 | 4 | Female | 10 | 292 |
| V2 | 5 | Female | 13 | 596 | |
| V3 | 5 | Female | 11 | 1092 | |
| V4 | 14 | Female | 18 | 2176 | |
| VPA + AZT | VA1 | 7 | Female | 19 | 2418 |
| VA2 | 5 | Female | 17 | 246 | |
| VA3 | 13 | Female | 20 | 441 | |
| VA4 | 12 | Female | 15 | 1164 | |
| VA5 | 4 | Male | 19 | 2660 |
| Treatment . | Monkey ID . | Age, y . | Sex . | Weight, kg . | Initial proviral load, copies/105 PBMCs . |
|---|---|---|---|---|---|
| None | C1 | 16 | Female | 19 | 519 |
| C2 | 20 | Male | 27 | 153 | |
| C3 | 11 | Male | 32 | 92 | |
| C4 | 15 | Female | 15 | 147 | |
| AZT | A1 | 14 | Female | 14 | 108 |
| A2 | 10 | Female | 22 | 86 | |
| VPA | V1 | 4 | Female | 10 | 292 |
| V2 | 5 | Female | 13 | 596 | |
| V3 | 5 | Female | 11 | 1092 | |
| V4 | 14 | Female | 18 | 2176 | |
| VPA + AZT | VA1 | 7 | Female | 19 | 2418 |
| VA2 | 5 | Female | 17 | 246 | |
| VA3 | 13 | Female | 20 | 441 | |
| VA4 | 12 | Female | 15 | 1164 | |
| VA5 | 4 | Male | 19 | 2660 |
Fifteen STLV-1–infected Papio papio were given daily a dose of VPA and/or AZT orally. The STLV-1 proviral load values are presented as the Tax copy number per 105 PBMCs at the initiation of the treatment. These values were also determined a month before the initiation of the trial and were found to be similar.
PBMCs indicates peripheral blood mononuclear cells; AZT, azidothymidine; VPA, valproate; and STLV-1, simian T-lymphotropic virus type 1.